Corrigendum to “Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes” [The Journal of Prevention of Alzheimer's Disease (2026) 100507]

20260 citationsJournal Articlediamond Open Access

Authors

Richard Perry · Imperial College London

Christopher Kipps · University Hospital Southampton NHS Foundation Trust

María Martín · Université Fédérale de Toulouse Midi-Pyrénées

Marco Bozzali · Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Giancarlo Logroscino · University of Bari Aldo Moro

Sarah J. Trafford · Eisai (United Kingdom)

Shobha Dhadda

Abstract

Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]

Topics & Keywords

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Cholinesterase and Neurodegenerative Diseases

Publication Details

Published in: The Journal of Prevention of Alzheimer s Disease

Volume 13, Issue 4, pp. 100527-100527

DOI: 10.1016/j.tjpad.2026.100527

Field-Weighted Citation Impact: 0.00

Command Palette

Corrigendum to “Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes” [The Journal of Prevention of Alzheimer's Disease (2026) 100507]

Authors

Abstract

Topics & Keywords

Publication Details